Form 4: Anebulo Pharmaceuticals CEO Acquires 254,433 Stock Options

Anebulo Pharmaceuticals CEO, Richard Anthony Cunningham, was granted 254,433 stock options on December 9, 2024, which vest immediately.

Summary

• Richard Anthony Cunningham, CEO of Anebulo Pharmaceuticals, was granted 254,433 stock options on December 9, 2024.
• The options have an exercise price of $1.56 per share.
• These options vest immediately upon grant.
• The options expire on December 8, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. The immediate vesting is slightly more aggressive, but not unusual.

Positives

• The immediate vesting of the options may act as an incentive for the CEO.
• The grant of options aligns the CEO's interests with those of shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant is not unusual for a CEO of a company of Anebulo's size and stage of development.
• Immediate vesting is not uncommon, but can be seen as more aggressive than a phased vesting schedule.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase company value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Anebulo Pharmaceuticals, Richard Anthony Cunningham, CEO